* This product is for research use only. Not intended for use in the treatment or diagnosis of disease.
Equipped with state-of-the-art technology and developed with expert scientists, BOC Sciences offers efficient NSCLC Cells Transfection Kits to meet your research goals and budgets.
|BT-000047||NCI-H1299 Transfection Reagent||Inquiry|
|BT-000048||NCI-H1975 Transfection Reagent||Inquiry|
|BT-000049||NCI-H460 Transfection Reagent||Inquiry|
|BT-000050||A549 Transfection Reagent||Inquiry|
Lung cancer is a malignant disease that occurs in the lining or epidermis of bronchi. The major types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In patients with lung cancer, >65% are diagnosed with locally advanced or metastatic disease. Thus, NSCLC is a malignancy of poor prognosis. Various cell lines (estimated to be 300-400) have been established from SCLC and NSCLC, and established cell lines were widely disseminated and used by the scientific community worldwide. Lung cancer treatments and new advances in immunotherapy and targeted therapies are crucial for patient treatment.
NCI-H1299 cells were derived from a 43-year-old male with non-small cell lung cancer.
NCI-H1975 cells were isolated from non-small cell lung adenocarcinoma tissue from a female (no history of smoking) in July 1988.
NCI-H460 cells were discovered by AF Gazdar and his colleagues in 1982 from a man with large cell lung cancer.
A549 cells were derived from a 52-year-old white male with lung cancer in 1972.